Cobimetinib | List of Frontiers open access articles

Clinical Trial

Published on 09 Feb 2023

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

in Cancer Molecular Targets and Therapeutics

Paolo A. Ascierto
Eleonora Cioli
Vanna Chiarion-Sileni
Pietro Quaglino
Francesco Spagnolo
Massimo Guidoboni
Michele Del Vecchio
Ketty Peris
Paola Queirolo
Luisa Fioretto

Frontiers in Oncology

doi 10.3389/fonc.2023.1107307

4,497 views
3 citations

Brief Research Report

Published on 23 Nov 2022

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma

in Skin Cancer

Saba S. Shaikh
Yan Zang
Janel Hanmer
Hong Wang
Yan Lin
Diwakar Davar
Hassane M. Zarour
John M. Kirkwood
Yana G. Najjar

Frontiers in Oncology

doi 10.3389/fonc.2022.1022496

4,051 views
9 citations

Systematic Review

Published on 21 Apr 2022

Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis

in Skin Cancer

Ling Hong
Ping Huang
Xiaochun Zheng
Xiaolan Ye
Hongying Zhao
Jianwei Wang
Yanfei Shao

Frontiers in Oncology

doi 10.3389/fonc.2022.865656

5,061 views
2 citations

Case Report

Published on 14 Mar 2024

Case report: Targeted treatment strategies for Erdheim-Chester disease

in Cancer Molecular Targets and Therapeutics

Anita Gulyás
László Imre Pinczés
János Mátyus
Edit Végh
Judit Bedekovics
Judit Tóth
Sándor Barna
Zsolt Hunya
Imre Lőrinc Szabó
Annamária Gazdag

Frontiers in Oncology

doi 10.3389/fonc.2024.1305518

5,080 views
6 citations

Original Research

Published on 24 May 2021

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

in Skin Cancer

Katharina C. Kähler
Ralf Gutzmer
Friedegrund Meier
Lisa Zimmer
Markus Heppt
Anja Gesierich
Kai-Martin Thoms
Jochen Utikal
Jessica C. Hassel
Carmen Loquai

Frontiers in Oncology

doi 10.3389/fonc.2021.672172

3,674 views
2 citations

Original Research

Published on 14 Oct 2024

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study

in Skin Cancer

Igor V. Samoylenko
Yulia M. Kolontareva
Ekaterina V. Kogay
Natalia V. Zhukova
Igor A. Utyashev
Mikhail E. Ivannikov
Konstantin V. Menshikov
Maxim V. Zinkevich
Kristina V. Orlova
Yulia V. Vakhabova

Frontiers in Oncology

doi 10.3389/fonc.2024.1395378

3,369 views
5 citations

Original Research

Published on 06 Oct 2022

The hexosamine biosynthesis pathway-related gene signature correlates with immune infiltration and predicts prognosis of patients with osteosarcoma

in Cancer Immunity and Immunotherapy

Zexin Su
Chenyang Wang
Runsang Pan
Hongbo Li
Junkai Chen
Jianye Tan
Xiaobin Tian
Tiao Lin
Jingnan Shen

Frontiers in Immunology

doi 10.3389/fimmu.2022.1028263

6,962 views
13 citations

Original Research

Published on 31 Jan 2022

Adverse Effects of Vemurafenib on Skin Integrity: Hyperkeratosis and Skin Cancer Initiation Due to Altered MEK/ERK-Signaling and MMP Activity

in Skin Cancer

Marius Tham
Hans-Jürgen Stark
Anna Jauch
Catherine Harwood
Elizabeth Pavez Lorie
Petra Boukamp

Frontiers in Oncology

doi 10.3389/fonc.2022.827985

6,468 views
7 citations

Review

Published on 22 Dec 2022

Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders

in Pharmacology of Anti-Cancer Drugs

Elsa Maitre
Jerome Paillassa
Xavier Troussard

Frontiers in Oncology

doi 10.3389/fonc.2022.1068981

7,891 views
13 citations

Articles

Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study

Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma

Acceptability of Drugs in the Treatment of Unresectable/Metastatic BRAF V600-Mutant Melanoma: A Systematic Review and Network Meta-Analysis

Case report: Targeted treatment strategies for Erdheim-Chester disease

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study

The hexosamine biosynthesis pathway-related gene signature correlates with immune infiltration and predicts prognosis of patients with osteosarcoma

Adverse Effects of Vemurafenib on Skin Integrity: Hyperkeratosis and Skin Cancer Initiation Due to Altered MEK/ERK-Signaling and MMP Activity

Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders